---
title: "Hanx Biopharmaceuticals Sets Out Board and Committee Structure"
description: "Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced its board composition, led by chairman Dr. Zhang Faming, including executive, non-executive, and independent non-executive directors. The company"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275228301.md"
published_at: "2026-02-08T10:07:11.000Z"
---

# Hanx Biopharmaceuticals Sets Out Board and Committee Structure

> Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced its board composition, led by chairman Dr. Zhang Faming, including executive, non-executive, and independent non-executive directors. The company detailed its three key board committees—Audit, Nomination, and Remuneration—clarifying the roles of chairpersons and members, enhancing corporate governance and transparency for shareholders. Hanx Biopharmaceuticals is listed in Hong Kong under stock code 3378, focusing on biologic drugs and therapies, with a current market cap of HK$2.19B.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H ( (HK:3378) ) is now available.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has announced the current composition of its board of directors, comprising executive, non-executive and independent non-executive directors, led by chairman Dr. Zhang Faming. The company has also detailed the membership and leadership of its three key board committees—Audit, Nomination and Remuneration—clarifying which directors serve as chairpersons and members of each committee, a move that underscores its corporate governance structure and provides greater transparency for shareholders and market participants regarding oversight responsibilities.

**More about Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H**

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong under stock code 3378. The company operates in the pharmaceutical and biotechnology industry, focusing on the research, development and commercialization of biologic drugs and related therapies.

**Average Trading Volume:** 574,993

**Current Market Cap:** HK$2.19B

Learn more about 3378 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [03378.HK - HANXBIO-B](https://longbridge.com/en/quote/03378.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hanx Biopharmaceuticals Files Director List with HKEX | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has submitted an updated director list to the Hong Kong Stock Exchange. The Boa | [Link](https://longbridge.com/en/news/275224008.md) |
| Hanx Biopharmaceuticals Doses First Patient in Phase I Trial of OX40-Targeted ADC HX111 | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has initiated a Phase I clinical trial for HX111, an OX40-targeting antibody-dr | [Link](https://longbridge.com/en/news/274815164.md) |
| Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection | Mikrobiomik has received approval in Spain for its oral therapy EUTEGRA (MBK-01) to treat Clostridioides difficile infec | [Link](https://longbridge.com/en/news/276345316.md) |
| Eu Commission Spokesperson: It Is In Remit Of Commission To Accept Such Invitations As The One From The U.s. To Participate In Board Of Peace Event | Eu Commission Spokesperson: It Is In Remit Of Commission To Accept Such Invitations As The One From The U.s. To Particip | [Link](https://longbridge.com/en/news/276436799.md) |
| 15:02 ETDisrupting Chronic Cough: Julian Circo Brings AI to the World's Oldest Symptom | Julian Circo, Co-Founder of Hyfe, discusses on the Disruption Interruption podcast how his company is revolutionizing re | [Link](https://longbridge.com/en/news/276373106.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.